Not applicableUnknownNCT02851329What this trial is testingTherapeutic Resistance Prediction of Tyrosine Kinase InhibitorsWho this might be right forNon-small Cell Lung Cancer Chinese Academy of Sciences 500
Early research (Phase 1)UnknownNCT04397926What this trial is testingPhase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung CancerWho this might be right forNon Small Cell Lung Cancer Sun Yat-sen University 20
Testing effectiveness (Phase 2)Looking for participantsNCT05987826What this trial is testingStudy of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLCWho this might be right forNon-Small Cell Lung Cancer Shanghai Zhongshan Hospital 40
Not applicableUnknownNCT03764917What this trial is testingNGS Combined With RNAseq on Tumor Immune Escape in NSCLCWho this might be right forNon-small Cell Lung Cancer Shanghai Pulmonary Hospital, Shanghai, China 100
Early research (Phase 1)Not Yet RecruitingNCT06067776What this trial is testingOsimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell CancerWho this might be right forMetastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8 Jonathan Riess 36
Not applicableStudy completedNCT07267247What this trial is testingCancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung CancerWho this might be right forNon-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)Drug-Related Side Effects and Adverse Reactions (MeSH Term)Egfr Tyrosine Kinase Inhibitor+1 more Taichung Veterans General Hospital 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT01553942What this trial is testingAfatinib With CT and RT for EGFR-Mutant NSCLCWho this might be right forLung Cancer Massachusetts General Hospital 19
Testing effectiveness (Phase 2)Enrolling By InvitationNCT06250777What this trial is testingEfficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain MetastasesWho this might be right forNon Small Cell Lung Cancer Yonsei University 27
Testing effectiveness (Phase 2)Study completedNCT05017025What this trial is testingAurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung CancerWho this might be right forAdvanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8+6 more M.D. Anderson Cancer Center 32
Early research (Phase 1)Active Not RecruitingNCT03333343What this trial is testingStudy of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCWho this might be right forEGFR-mutant Non-small Cell Lung Cancer Novartis Pharmaceuticals 105
Testing effectiveness (Phase 2)UnknownNCT05244213What this trial is testingNeoadjuvant Immunotherapy in EGFR-mutant Localized NSCLCWho this might be right forNon-small Cell Lung CancerEGFR Activating Mutation Guangdong Provincial People's Hospital 35
Testing effectiveness (Phase 2)Study completedNCT01415011What this trial is testingEfficacy and Safety Study of Afatinib to Treat Lung Cancer PatientsWho this might be right forCarcinoma, Non-Small-Cell Lung University College, London 39
Testing effectiveness (Phase 2)Ended earlyNCT06186076What this trial is testingInvestigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC PatientsWho this might be right forCarcinoma, Non-Small-Cell LungEGFR Mutant Advanced Non-Small Cell Lung Cancer Therapex Co., Ltd 19
Early research (Phase 1)Study completedNCT01320059What this trial is testingStudy of 18F-Fluoro-PEG6-IPQAWho this might be right forLung Cancer M.D. Anderson Cancer Center 6
Testing effectiveness (Phase 2)Ended earlyNCT02770014What this trial is testingRapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung CancerWho this might be right forEpidermal Growth Factor ReceptorNon-Small Cell Lung Cancer Dana-Farber Cancer Institute 43
Early research (Phase 1)UnknownNCT02321293What this trial is testingProspective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLCWho this might be right forLung Cancer Lady Davis Institute 20
Early research (Phase 1)Study completedNCT02191891What this trial is testingXentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)Who this might be right forCarcinoma, Non-Small-Cell Lung Boehringer Ingelheim 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT03667820What this trial is testingStudy of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLCWho this might be right forNon-small Cell Lung Cancer (NSCLC) University of Texas Southwestern Medical Center 41
Testing effectiveness (Phase 2)UnknownNCT05534113What this trial is testingEnvafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLCWho this might be right forNon-small Cell Lung Cancer The First Affiliated Hospital with Nanjing Medical University 38
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07413952What this trial is testingLimertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain MetastasesWho this might be right forNSCLC The First Affiliated Hospital of Guangzhou Medical University 45